According to Materialise,” 3D printing is a slow revolution. But it is a revolution regardless when you consider what the technology does: saving lives, enabling new business models, redefining how we design products. But none of that happened overnight. The revolutionary nature of 3D printing grew over the decades, formed on a foundation of small but valuable steps.”
Materialise incorporates nearly 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry.
According to Materialise,” Let’s discuss ways how we can empower people to design, collaborate, build, and fabricate in more sustainable ways, while reducing waste, saving money, and staying competitive. At the end of the second quarter of 2019, the total commitment of lease assets and liabilities amounted to 5,050 kEUR. Our Adjusted EBITDA for the second quarter of 2019 was affected positively by the new standard as a result of the rental payments decrease of 644 kEUR; however, our operating profit was impacted by only 52 kEUR as depreciation expenses increased by 593 kEUR.
Materialise, Will acquire a mix of existing and new shares bringing its total shareholding to 75%, with the founding shareholders retaining the remaining 25%. All shares will be fully paid for in cash at the closing, which is expected to take place during the week of August 5, 2019.”
According to Materialise reports the Second quarter and now, 2019 Results, Executive Chairman Peter Leys commented, “In spite of a macro-economic environment that continues to be challenging, Materialise reported another quarter of top-line growth. This was mainly driven by Materialise Medical, which continued to perform strongly with solid revenue growth and EBITDA performance, and also by Materialise Manufacturing, which realized a double-digit EBITDA margin and grew its revenues for the third consecutive quarter.
This quarter, the contribution by Materialise Software to our revenue growth and Adjusted EBITDA margin was below our expectations as a number of sales were pushed out to the second half of the year. Our outlook for 2019 remains within our previous guidance range, with our results now including expected contributions from our August acquisition of a 75% stake in Engimplan.
This investment, which will enable us to introduce the benefits of Materialise’s patient-specific 3D printing implants and expertise to the fast-growing Brazil market, is part of our strategy to accelerate our growing presence in the additive manufacturing ecosystem through carefully selected acquisitions and partnerships.”
According to Materialise, “you will discover how Streamics, as an AM production management and control system, enables service providers and bureaus as well as end-part manufacturers to get the most out of the potential that 3D printing has to offer.”
According to Essentium co-founder and CEO Blake Teipel, “Industrial additive manufacturing is ripe for transformation. The problem/solution paradigm is made clear through independent research we commissioned among executives in industrial manufacturing where 100 percent of respondents reported obstacles in using 3D printing for large scale production, and 88% stated that their industries will save billions of dollars in production costs when the barriers are eliminated. Eliminating these barriers is what Essentium is delivering on. The developer of the High Speed Extrusion (HSE) FDM 3D printing platform, has closed a $22.2 million series A funding round. Led by BASF Venture Capital, the round featured the participation of award-winning 3D software company Materialise, Houston private equity firm Genesis Park, and previous seed round investors”.
According to the Materialise World Conference, ” 2015 invites world’s leading thinkers and doers in 3D printing, from clinical, to biomedical, to industrial, Engineering, and other fields and companies that have the visionary approach.
It will provide a forum to discuss various topics including safer and better solutions for patients, the added value of 3D printers for current and future medical applications, and how will these evolve”.:)
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
